Bristol Myers Squibb in an all-cash deal at $5 per share, with the merger set to close in Q2 2025. Despite Abecma generating $242 million in U.S. sales, 2seventy still booked a $3.3 million loss from ...

Shares of Bristol Myers Squibb Co. slid 3.05% to $59.19 Tuesday, on what proved to be an all-around favorable trading session ...

Bearish flow noted in Bristol Myers ( BMY) Squibb with 13,765 puts trading, or 2x expected. Most active are Apr-25 60 puts and 4/4 weekly 60 puts, with total volume in those strikes near 8,600 ...

BMY has enjoyed robust capital appreciation over the past few months, significantly aided by the ongoing market rotation to ...

Analysts have taken a lukewarm stance on Bristol-Myers Squibb, dishing out a mixed bag of stock ratings that’s less “fireworks” and more “flickering candle.” Out of nineteen brokerages, eleven slapped ...

We recently published a list of the 15 Best and Cheap Stocks to Buy According to Billionaires. In this article, we are going ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

More than a year into a strategic pivot to zero in on the multiple myeloma cell therapy Abecma, 2seventy bio is selling itself to partner Bristol Myers Squibb. Bristol Myers has agreed to buy out ...

Shares of 2seventy bio took flight Tuesday after the biotechnology company agreed to be acquired by partner Bristol Myers Squibb. Bristol Myers is paying $5 a share in cash for 2seventy ...

2seventy bio, Inc. (Nasdaq: TSVT), today announced a definitive merger agreement under which Bristol Myers Squibb (NYSE: BMY) (“BMS”) will acquire all of the outstanding shares ...

(RTTNews) - 2seventy bio Inc. (TSVT) agreed to be acquired by Bristol Myers Squibb (BMY) at a price of $5.00 per share in an all-cash transaction. This acquisition values the total equity at ...

Bristol Myers Squibb is acquiring 2seventy bio, a deal that gives the pharmaceutical giant full control over the partnered cancer cell therapy Abecma as that product faces headwinds in a ...